Arrowhead Pharmaceuticals (ARWR) Financials: Revenue & Earnings
ARWR$59.29+0.26 +0.44%
$8.37B
Market Cap
-26.33
P/E
13.46
Forward P/E
60
Score
Arrowhead Pharmaceuticals (ARWR) Financials: Revenue & Earnings
ARWR price $59.29 +0.26 +0.44%
- Ticker
- ARWR
- Price
- $59.29
- Change
- +0.26 +0.44%
- Market cap ?
- $8.37B
- P/E ?
- -26.33
- Forward P/E ?
- 13.46
- Dividend yield ?
- 0.00%
- Beta ?
- 1.30
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 60
- Value
- 55
- Quality
- 35
- Growth
- 89
Stocklytics score rationale: value 55, quality 35, growth 89.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 158333 | 31407709 | 16142321 | 168796000 | 87992000 | 138287000 | 243231000 | 240735000 | 3551000 | 829448000 |
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II…
Fair value
ARWR fair value $94.78. Price $59.29. Price is 37% below fair value.
Above fair value, and more expensive than usual. A larger premium than on 83% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 239.15M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 11.47% (beta 1.3). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 141.25M. Net debt 139.74M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-24 | — | -1.52 | — | 61.18M |
| 2026-08-04 | -1.36 | -1.28 | 75.25M | 44.17M |
| 2026-05-07 | -0.93 | -1.09 | 73.74M | 73.84M |
| 2026-02-05 | 0.22 | 0.60 | 264.03M | 213.94M |
| 2025-11-25 | -0.18 | -0.11 | 256.47M | 175.32M |
| 2025-08-07 | -1.26 | -0.94 | 27.77M | 154.06M |
| 2025-05-12 | 2.75 | -0.06 | 542.71M | 116.27M |
| 2025-02-10 | -1.39 | -0.42 | 2.50M | 19.05M |
| 2024-11-26 | -1.38 | -1.05 | 3.55M | 55.07M |
| 2024-08-08 | -1.38 | -0.58 | — | 69.67M |
| 2024-05-09 | -1.02 | -0.06 | — | 63.87M |
| 2024-02-06 | -1.24 | -0.78 | 3.55M | 29.51M |
| 2023-11-29 | -1.03 | -0.70 | 16.10M | 50.73M |
| 2023-08-07 | -0.96 | -0.58 | 15.82M | 59.82M |
| 2023-05-02 | 0.45 | -0.64 | 146.27M | 45.48M |
| 2023-02-06 | -0.39 | 1.14 | 62.55M | 162.52M |
| 2022-11-28 | -0.81 | -0.57 | 31.57M | 50.30M |
| 2022-08-04 | -0.68 | -0.45 | 32.41M | 45.75M |
| 2022-05-10 | 0.41 | -0.08 | 151.81M | 122.15M |
| 2022-02-02 | -0.60 | -0.22 | 27.44M | 47.81M |
| 2021-11-22 | -0.61 | -0.11 | 38.28M | 37.23M |
| 2021-08-05 | -0.29 | -0.08 | 45.89M | 37.52M |
| 2021-05-04 | -0.26 | -0.09 | 32.81M | 37.70M |
| 2021-02-04 | -0.20 | 1.00 | 21.30M | 79.46M |
| 2020-11-23 | -0.48 | 0.34 | 7.63M | 41.22M |
| 2020-08-05 | -0.13 | -0.07 | 27.38M | 25.27M |
| 2020-05-07 | -0.20 | -0.11 | 23.53M | 15.88M |
| 2020-02-05 | -0.03 | -0.01 | 29.45M | 9.82M |
| 2019-11-25 | 0.11 | 0.16 | 43.29M | 62.97M |
| 2019-08-05 | 0.21 | 0.29 | 42.70M | 58.96M |
| 2019-05-08 | 0.24 | 0.19 | 48.15M | 38.12M |
| 2019-02-07 | 0.13 | 0.54 | 34.66M | 143.96M |
| 2018-12-11 | -0.12 | -0.17 | 11.26M | 10.32M |
| 2018-08-07 | -0.18 | -0.19 | 727.38K | 730.00K |
| 2018-05-08 | -0.18 | -0.18 | 650.12K | 650.00K |
| 2018-02-09 | -0.18 | -0.18 | 3.51M | 3.12M |
| 2017-12-12 | -0.14 | -0.12 | 8.71M | 5.81M |
| 2017-08-03 | -0.07 | -0.13 | 9.34M | 18.68M |
| 2017-05-03 | -0.08 | -0.12 | 8.99M | 13.48M |
| 2017-02-06 | -0.17 | -0.18 | 4.37M | 5.14M |
Dividends
Yield 0.00%. Payout ratio —. Frequency —.
Safety score 24/100 · At risk. Payout ratio is not reported, so this part stays neutral. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-18 | OLUKOTUN ADEOYE Y | Sell | 2.00K | $86.96 | 173.92K |
| 2026-08-18 | PERRY MICHAEL S | Sell | 11.60K | $87.30 | 1.01M |
| 2026-06-15 | Cohen Matthew Gregory | Buy | 11.88K | — | — |
| 2026-06-15 | Cohen Matthew Gregory | Other | 0 | — | — |
| 2026-05-12 | Lu Hongbo | Sell | 2.97K | $76.88 | 228.33K |
| 2026-04-23 | Hamilton James C | Sell | 10.00K | $75.00 | 750.00K |
| 2026-04-22 | Apel Daniel Joseph | Sell | 3.21K | $70.11 | 224.91K |
| 2026-04-22 | Apel Daniel Joseph | Sell | 1.16K | $70.45 | 81.51K |
| 2026-04-22 | Apel Daniel Joseph | Sell | 8.73K | $71.92 | 627.86K |
| 2026-03-05 | Hamilton James C | Sell | 10.00K | $64.19 | 641.90K |
| 2026-01-06 | Hamilton James C | Buy | 75.00K | — | — |
| 2026-01-06 | Apel Daniel Joseph | Buy | 75.00K | — | — |
| 2026-01-06 | O'Brien Patrick | Buy | 75.00K | — | — |
| 2026-01-06 | O'Brien Patrick | Sell | 540 | — | — |
| 2026-01-06 | O'Brien Patrick | Sell | 540 | — | — |
| 2026-01-06 | O'Brien Patrick | Sell | 540 | — | — |
| 2026-01-06 | O'Brien Patrick | Sell | 440 | — | — |
| 2026-01-06 | O'Brien Patrick | Sell | 440 | — | — |
| 2026-01-05 | O'Brien Patrick | Sell | 4.37K | $61.20 | 267.32K |
| 2026-01-05 | O'Brien Patrick | Sell | 6.16K | $62.23 | 383.59K |
| 2026-01-05 | O'Brien Patrick | Sell | 13.45K | $62.96 | 846.87K |
| 2026-01-05 | O'Brien Patrick | Sell | 11.84K | $63.84 | 755.99K |
| 2026-01-05 | O'Brien Patrick | Sell | 2.70K | $64.44 | 173.99K |
| 2026-01-05 | O'Brien Patrick | Sell | 900 | $66.01 | 59.41K |
| 2026-01-05 | O'Brien Patrick | Sell | 313 | $68.00 | 21.28K |
| 2026-01-05 | O'Brien Patrick | Sell | 600 | $61.12 | 36.67K |
| 2026-01-05 | O'Brien Patrick | Sell | 900 | $62.25 | 56.02K |
| 2026-01-05 | O'Brien Patrick | Sell | 5.87K | $62.91 | 369.47K |
| 2026-01-05 | O'Brien Patrick | Sell | 2.34K | $64.04 | 149.60K |
| 2026-01-05 | O'Brien Patrick | Sell | 46 | $68.00 | 3.13K |
| 2026-01-05 | Hamilton James C | Sell | 4.62K | $61.24 | 283.24K |
| 2026-01-05 | Hamilton James C | Sell | 6.09K | $62.28 | 379.29K |
| 2026-01-05 | Hamilton James C | Sell | 14.79K | $63.01 | 932.04K |
| 2026-01-05 | Hamilton James C | Sell | 12.71K | $63.95 | 812.87K |
| 2026-01-05 | Hamilton James C | Sell | 1.20K | $64.49 | 77.39K |
| 2026-01-05 | Hamilton James C | Sell | 437 | $65.97 | 28.83K |
| 2026-01-05 | Hamilton James C | Sell | 309 | $68.00 | 21.01K |
| 2026-01-02 | Anzalone Christopher Richard | Sell | 7.42K | $65.88 | 488.57K |
| 2026-01-02 | Anzalone Christopher Richard | Sell | 5.77K | $66.39 | 383.14K |
| 2025-12-31 | O'Brien Patrick | Sell | 560 | — | — |
| 2025-12-31 | O'Brien Patrick | Sell | 560 | — | — |
| 2025-12-31 | O'Brien Patrick | Sell | 560 | — | — |
| 2025-12-31 | O'Brien Patrick | Sell | 560 | — | — |
| 2025-12-31 | O'Brien Patrick | Sell | 560 | — | — |
| 2025-12-29 | Anzalone Christopher Richard | Buy | 16.55K | $6.15 | 101.75K |
| 2025-12-29 | Anzalone Christopher Richard | Buy | 35.18K | $6.15 | 216.36K |
| 2025-12-29 | Anzalone Christopher Richard | Sell | 35.18K | $69.33 | 2.44M |
| 2025-12-29 | Anzalone Christopher Richard | Sell | 16.55K | $68.69 | 1.14M |
| 2025-12-29 | Anzalone Christopher Richard | Sell | 35.18K | $6.15 | 216.36K |
| 2025-12-29 | Anzalone Christopher Richard | Sell | 16.55K | $6.15 | 101.75K |
| 2025-12-26 | Ferrari Mauro | Sell | 7.53K | $70.00 | 527.10K |
| 2025-12-22 | Anzalone Christopher Richard | Sell | 10.01K | $68.33 | 684.12K |
| 2025-12-22 | Anzalone Christopher Richard | Sell | 2.57K | $68.85 | 177.22K |
| 2025-12-19 | Waddill William D. | Sell | 2.42K | $66.66 | 161.05K |
| 2025-12-19 | Waddill William D. | Sell | 5.45K | $68.01 | 370.72K |
| 2025-12-19 | Waddill William D. | Sell | 500 | $68.53 | 34.27K |
| 2025-12-19 | Vakiener Victoria | Sell | 2.80K | $66.63 | 186.50K |
| 2025-12-19 | Vakiener Victoria | Sell | 5.28K | $67.97 | 358.95K |
| 2025-12-19 | Vakiener Victoria | Sell | 1.96K | $68.39 | 134.04K |
| 2025-12-19 | Anzalone Christopher Richard | Sell | 3.98K | $66.67 | 265.28K |
| 2025-12-19 | Anzalone Christopher Richard | Sell | 8.15K | $68.01 | 554.08K |
| 2025-12-19 | Anzalone Christopher Richard | Sell | 1.32K | $68.48 | 90.33K |
| 2025-12-19 | OLUKOTUN ADEOYE Y | Sell | 3.09K | $66.70 | 206.10K |
| 2025-12-19 | OLUKOTUN ADEOYE Y | Sell | 6.08K | $68.04 | 413.89K |
| 2025-12-19 | OLUKOTUN ADEOYE Y | Sell | 827 | $68.48 | 56.63K |
| 2025-12-17 | Anzalone Christopher Richard | Sell | 46.29K | $63.55 | 2.94M |
| 2025-12-17 | Anzalone Christopher Richard | Sell | 35.75K | $64.51 | 2.31M |
| 2025-12-17 | Anzalone Christopher Richard | Sell | 982 | $65.53 | 64.35K |
| 2025-12-17 | Anzalone Christopher Richard | Sell | 1.98K | $66.30 | 131.34K |
| 2025-12-16 | Ferrari Mauro | Buy | 7.82K | — | — |
| 2025-12-16 | Lu Hongbo | Buy | 7.82K | — | — |
| 2025-12-16 | PERRY MICHAEL S | Buy | 7.82K | — | — |
| 2025-12-16 | Vakiener Victoria | Buy | 7.82K | — | — |
| 2025-12-16 | INGRAM DOUGLAS S | Buy | 7.82K | — | — |
| 2025-12-16 | OLUKOTUN ADEOYE Y | Buy | 7.82K | — | — |
| 2025-12-16 | Waddill William D. | Buy | 7.82K | — | — |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 8.42K | $60.51 | 509.25K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 10.96K | $61.25 | 671.48K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 14.10K | $62.12 | 875.58K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 8.48K | $62.94 | 533.48K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 6.66K | $64.29 | 428.24K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 1.00K | $64.96 | 64.96K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 1.30K | $65.77 | 85.50K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 166 | $66.77 | 11.08K |
| 2025-12-16 | Anzalone Christopher Richard | Sell | 3.22K | $67.87 | 218.61K |
| 2025-12-15 | Anzalone Christopher Richard | Sell | 100.53K | $68.67 | 6.90M |
| 2025-12-15 | Anzalone Christopher Richard | Sell | 21.32K | $69.28 | 1.48M |
| 2025-12-15 | Anzalone Christopher Richard | Sell | 8.15K | $69.96 | 569.96K |
| 2025-12-12 | Anzalone Christopher Richard | Buy | 180.00K | — | — |
| 2025-12-05 | PERRY MICHAEL S | Sell | 16.25K | $61.03 | 991.74K |
| 2025-11-28 | Ferrari Mauro | Sell | 8.75K | $56.39 | 493.41K |
| 2025-10-01 | Hamilton James C | Sell | 20.00K | $35.00 | 700.00K |
| 2025-09-12 | Hamilton James C | Sell | 15.00K | $30.00 | 450.00K |
| 2025-09-02 | Hamilton James C | Sell | 15.00K | $25.00 | 375.00K |
| 2025-08-15 | Hamilton James C | Sell | 9.39K | $20.00 | 187.78K |
| 2025-08-13 | Hamilton James C | Sell | 611 | $20.00 | 12.22K |
| 2025-04-15 | Apel Daniel Joseph | Other | 0 | — | — |
| 2025-04-11 | Anzalone Christopher Richard | Sell | 50.80K | $11.49 | 583.69K |
| 2025-04-10 | Anzalone Christopher Richard | Sell | 50.00K | $10.87 | 543.50K |
| 2025-04-09 | Anzalone Christopher Richard | Sell | 35.30K | $9.93 | 350.58K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 523, holders +62 vs prior quarter. Ownership 83.88%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| BLACKROCK, INC. | 14.83M | -3.33M | -18.34% | 1.21B |
| AVORO CAPITAL ADVISORS LLC | 11.36M | 655.56K | +6.13% | 925.59M |
| FMR LLC | 8.04M | 773.15K | +10.64% | 655.32M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.35M | -794.78K | -11.12% | 517.70M |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.11M | 78.54K | +1.30% | 498.10M |
| STATE STREET CORP | 5.69M | -801.49K | -12.34% | 464.17M |
| NORGES BANK | 3.90M | 3.90M | New | 317.61M |
| INVESCO LTD. | 3.88M | 603.33K | +18.39% | 316.58M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.53M | -748.22K | -17.49% | 298.81M |
| FRED ALGER MANAGEMENT, LLC | 3.30M | -40.57K | -1.21% | 269.14M |
| BAKER BROS. ADVISORS LP | 1.99M | 0 | 0.00% | 162.43M |
| SIREN, L.L.C. | 1.72M | 100.00K | +6.19% | 139.83M |
| VESTAL POINT CAPITAL, LP | 1.57M | -700.00K | -30.77% | 128.38M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1.39M | -184.24K | -11.71% | 113.22M |
| FIRST TRUST ADVISORS LP | 1.35M | 1.20M | +807.10% | 110.28M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.35M | 160.22K | +13.46% | 110.08M |
| JUPITER TOPCO LLC | 1.22M | 1.22M | New | 99.62M |
| NORTHERN TRUST CORP | 1.19M | -462.97K | -27.96% | 97.23M |
| DIMENSIONAL FUND ADVISORS LP | 1.18M | 573.08K | +94.17% | 96.31M |
| GOLDMAN SACHS GROUP INC | 1.15M | -589.92K | -33.90% | 93.74M |
| BANK OF AMERICA CORP /DE/ | 1.14M | 75.36K | +7.08% | 92.91M |
| HOOD RIVER CAPITAL MANAGEMENT LLC | 1.12M | 64.21K | +6.08% | 91.35M |
| HOLOCENE ADVISORS, LP | 1.11M | 1.11M | New | 90.16M |
| MORGAN STANLEY | 1.08M | 124.33K | +12.94% | 88.43M |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 964.48K | -366.52K | -27.54% | 78.61M |
Earnings and financials
Arrowhead Pharmaceuticals, Inc. (ARWR) trades at $59.29, with a market cap of $8.37B and a trailing P/E of -26.33. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 158333 | 31407709 | 16142321 | 168796000 | 87992000 | 138287000 | 243231000 | 240735000 | 3551000 | 829448000 |
Insights · Dividends · Forecast · Financials · Learn